Exelixis’ collaborator Daiichi Sankyo launches MINNEBRO (Esaxerenone) tablets in Japan

This article was originally published here

With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under the terms of the companies’ collaboration agreement.

The post Exelixis’ collaborator Daiichi Sankyo launches MINNEBRO (Esaxerenone) tablets in Japan appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply